Clinical Trial Update: Efficacy and Safety Study of Escitalopram Augmentation in Treatment Resistant Schizophrenia [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating the efficacy and safety of adding escitalopram to ongoing treatment in treatment-resistant schizophrenia and schizoaffective disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizoaffective Disorder
• Schizophrenia

Drugs mentioned

• Escitalopram (escitalopram)

Snippet

Sponsor: Emory University | Conditions: Schizophrenia, Schizoaffective Disorder | Phase 4 | Status: COMPLETED